Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.
Our business is organized into three segments — North America, Europe and Rest of World. This reflects how we manage our global platform — as one business across all product and channel types.
Rest of World
Our Rest of World segment is made up primarily of our operations in Japan, Australia, China, Brazil, Russia, India, South Africa and certain markets in the Middle-East and South East Asia.
In 2017, the Rest of World segment accounted for approximately 24% of Mylan’s net third party sales. Read more about Mylan’s 2017 financial performance.
India is home to nearly half of Mylan’s workforce and approximately half of its manufacturing facilities. Moreover, approximately a quarter of the company’s regulatory professionals and scientists are based in Hyderabad, where they work in one of Mylan’s global R&D centers. We also have a significant presence in Bangalore, which is where we have many injectables facilities and from which we manage our commercial activities, including our antiretroviral (ARV) and third-party active pharmaceutical ingredients businesses. Mylan’s robust commercial presence in India has made it the fastest growing multinational company in India with strong representation in therapeutic franchises such as hepatitis, oncology and critical care.
Since 2007, Mylan has been instrumental in increasing access to life-saving ARVs and has a majority market share in sub-Saharan African countries such as Zambia, Zimbabwe, Kenya, Nigeria and Cameroon. We are the number one provider of antiretroviral medicines in the developing world with a focus on Africa. Key to this achievement has been our success in introducing high quality USFDA-approved and WHO-prequalified products.
Mylan has been among the fastest growing companies in the Japan generics market for the last three years. We also maintain manufacturing capabilities in Japan, which play a key role in supplying our businesses throughout the country. Japan is the world’s third largest pharmaceutical market by value and the fifth largest generic prescription market by volume.
We hold a leading position in Australia's generic pharmaceuticals market, in terms of volume.
With our recent acquisition of Meda, we have accelerated our expansion in attractive emerging markets, such as China, Russia, South East Asia and the Middle-East.
We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.
These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well.
When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.
If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.